quinazolines has been researched along with Alloxan Diabetes in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.65) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 10 (23.26) | 29.6817 |
| 2010's | 23 (53.49) | 24.3611 |
| 2020's | 4 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Liao, J; Lu, Q; Niu, C; Wang, H; Wang, S; Yu, Y | 1 |
| Al-Marzooki, Z; Alasmari, MM; Alshaeri, HK; Bamanie, FH; El-Zahabi, MA; Ghareeb, S; Moustafa, M; Zayed, MF | 1 |
| Devi, RV; Singh, CB; Singh, OJ; Surbala, L | 1 |
| Cui, WF; Ge, WJ; Li, BJ; Li, GS; Liang, RF; Song, XM; Zhang, SF; Zhang, YY | 1 |
| Han, J; Liang, G; Qian, Y; Wang, J; Weng, Q; Xu, Z; Zhao, Y; Zhong, P; Zou, C | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Klupczynska, A; Kokot, ZJ; Moch, M; Plewa, S; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Akhtar, M; Akhtar, MS; Hassan, MQ; Najmi, AK; Paudel, YN; Shah, S | 1 |
| Abdelkader, NM; Abou-Seri, SM; Mohamed, MA; Taha, AM | 1 |
| Choung, S; Joung, KH; Kim, HJ; Kim, JM; Ku, BJ; Lee, ES | 1 |
| Shannon, RP | 1 |
| Advani, A; Advani, SL; Connelly, KA; Gilbert, RE; Kelly, DJ; Thai, K; Zhang, Y | 1 |
| Parveen, G; Rathore, A; Siddiqui, AA; Yar, MS | 1 |
| Dobrowsky, RT; Pan, P | 1 |
| Kontani, Y; Kusudo, T; Mori, N; Okamatsu, Y; Saito, M; Takeuchi, T; Wang, T; Yamashita, H; Yamashita, Y | 1 |
| Harris, RC; Paueksakon, P; Wang, Y; Zhang, MZ | 1 |
| Chan, KC; Chen, ML; Huang, CN; Peng, CH; Wang, CJ; Yang, YS | 1 |
| Hamaguchi, Y; Kawanami, T; Murase, K; Nagaishi, R; Nomiyama, T; Takahashi, H; Tanabe, M; Tanaka, T; Terawaki, Y; Yanase, T | 1 |
| Hu, J; Li, X; Liang, D; Liang, G; Lin, F; Qian, Y; Wang, J; Xu, Z; Zeng, C; Zhong, P | 1 |
| Byrne, FM; Chapman, V; Cheetham, S; Vickers, S | 1 |
| Akhtar, S; Al-Khaldi, AT; Attur, S; Benter, IF; Chandrasekhar, B; Dhaunsi, GS; Sarkhou, F; Yousif, MH | 1 |
| Barbera Betancourt, A; Cooke, A; Emery, JL; Okkenhaug, K; Recino, A; Wallberg, M; Wong, FS | 1 |
| Akhtar, S; Al-Zaid, B; Attur, S; Benter, IF; Chandrasekhar, B; El-Hashim, AZ | 1 |
| Akhtar, MJ; Ali, Z; Haider, MR; Khan, AA; Siddiqui, AA; Yar, MS | 1 |
| Kamijo, M; Matsuoka, N; Minoura, K; Mutoh, S; Shimoshige, Y; Takakura, S | 1 |
| Akhtar, S; Almubrad, T; Benter, IF; Bron, AJ; Yousif, MH | 1 |
| Gao, B; Gilbert, RE; Ingram, AJ; Kelly, DJ; Krepinsky, JC; Kumar, S; Peng, F; Wu, D; Zhang, B | 1 |
| Aoki, T; Enomoto, R; Kaneko, S; Matsuoka, N; Shimoshige, Y | 1 |
| Li, YX; Sun, Q; Wang, H; Wang, SN | 1 |
| Engelmann-Pilger, K; Frank, S; Klein, T; Linke, A; Mark, M; Pfeilschifter, J; Schürmann, C; Steinmetz, C | 1 |
| Alter, ML; Henze, A; Hocher, B; Klein, T; Krause-Relle, K; Ott, IM; Raila, J; Sharkovska, Y; Tsuprykov, O; von Websky, K | 1 |
| Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P | 1 |
| Ram, VJ; Srivastava, AK; Tripathi, BK | 1 |
| Cetkovic-Cvrlje, M; Dragt, AL; Uckun, FM | 1 |
| Akhtar, S; Benter, IF; Yousif, MH | 1 |
| Akhtar, S; Benboubetra, M; Benter, IF; Griffiths, SM; Yousif, MH | 1 |
| Esmat, AY; Gawad, SM; Ibrahim, AM; Mohamed, MA; Refaie, FM | 1 |
| Chatterjee, AK; Mukherjee, SK; Murthi, PS | 1 |
| Fukuhara, Y; Hisatomi, A; Ishida, H; Mitamura, T; Murato, K; Ohara, K; Takahashi, Y | 1 |
| Bursell, SE; Clermont, AC; Ishii, H; King, GL; Mori, F; Takagi, C; Takagi, H | 1 |
| Goto, T; Kawamura, I; Seki, J; Takakura, S; Yamamoto, T | 1 |
| Ao, S; Kikuchi, C; Notsu, Y; Ono, T | 1 |
| Akagi, Y; Ikebe, H; Mori, K; Nishikawa, H; Okamoto, S; Terubayashi, H; Tsutsumi, M; Yoshizaki, K | 1 |
| Mukherjee, SK | 1 |
43 other study(ies) available for quinazolines and Alloxan Diabetes
| Article | Year |
|---|---|
Serum untargeted metabolomics analysis of the mechanisms of evodiamine on type 2 diabetes mellitus model rats.
Topics: Amino Sugars; Animals; Arginine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glutathione; Metabolomics; Nucleotides; Proline; Quinazolines; Rats; Streptozocin; Tryptophan | 2022 |
Design, Synthesis, Molecular Modeling and Anti-Hyperglycemic Evaluation of Quinazoline-Sulfonylurea Hybrids as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Sulfonylurea Receptor (SUR) Agonists.
Topics: Animals; Diabetes Mellitus, Experimental; Glyburide; Humans; Hypoglycemic Agents; Molecular Docking Simulation; PPAR gamma; Quinazolines; Rats; Sulfonylurea Compounds; Sulfonylurea Receptors | 2022 |
Rutaecarpine exhibits anti-diabetic potential in high fat diet-multiple low dose streptozotocin induced type 2 diabetic mice and in vitro by modulating hepatic glucose homeostasis.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Glucose; Homeostasis; Hypoglycemic Agents; Indole Alkaloids; Liver; Male; Mice, Inbred C57BL; Quinazolines | 2020 |
Rutaecarpine enhances the anti-diabetic activity and hepatic distribution of metformin via up-regulation of Oct1 in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Indole Alkaloids; Liver; Metformin; Quinazolines; Rats; Up-Regulation | 2021 |
EGFR inhibition attenuates diabetic nephropathy through decreasing ROS and endoplasmic reticulum stress.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; ErbB Receptors; Humans; Mice; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Streptozocin; Transforming Growth Factor beta; Tyrphostins | 2017 |
A pharmacokinetic study on lapatinib in type 2 diabetic rats.
Topics: Animals; Antineoplastic Agents; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Lapatinib; Male; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Tandem Mass Spectrometry | 2018 |
EGFR tyrosine kinase inhibition decreases cardiac remodeling and SERCA2a/NCX1 depletion in streptozotocin induced cardiomyopathy in C57/BL6 mice.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; ErbB Receptors; Gefitinib; Mice; Mice, Inbred C57BL; Myocardium; Protein Kinase Inhibitors; Quinazolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Calcium Exchanger | 2018 |
New Quinazoline-Sulfonylurea Conjugates: Design, Synthesis and Hypoglycemic Activity.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Down-Regulation; Female; Glucose Transporter Type 2; Glucose Transporter Type 4; Glyburide; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Molecular Structure; Muscle, Skeletal; Pancreas; Quinazolines; Rats, Sprague-Dawley; Structure-Activity Relationship; Up-Regulation | 2019 |
Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice.
Topics: Animals; Cell Line, Tumor; Diabetes Mellitus, Experimental; Dietary Fats; ErbB Receptors; Humans; Lipogenesis; Male; Mice; Non-alcoholic Fatty Liver Disease; Quinazolines; Signal Transduction | 2019 |
DPP-4 inhibition and neuroprotection: do mechanisms matter?
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines; Stroke; Sulfonylurea Compounds | 2013 |
Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Experimental; Hypertension; Kidney; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Piperidines; Proteinuria; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Systole | 2013 |
Synthesis and characterization of quinazoline derivatives: search for hybrid molecule as diuretic and antihypertensive agents.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diuretics; Dose-Response Relationship, Drug; Hypertension; Hypoglycemic Agents; Molecular Structure; Quinazolines; Rats; Structure-Activity Relationship | 2014 |
Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy.
Topics: Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Progression; Down-Regulation; Erlotinib Hydrochloride; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Neural Conduction; Neuregulin-1; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sural Nerve | 2013 |
Evodiamine inhibits insulin-stimulated mTOR-S6K activation and IRS1 serine phosphorylation in adipocytes and improves glucose tolerance in obese/diabetic mice.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Evodia; Female; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Mice, Obese; Phosphorylation; Quinazolines; Ribosomal Protein S6 Kinases; Serine; Signal Transduction; TOR Serine-Threonine Kinases | 2013 |
Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy.
Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Blood Glucose; Blood Pressure; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Immunohistochemistry; Kidney; Mice; Mice, Inbred NOD; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2014 |
Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Epithelial-Mesenchymal Transition; Glucose; Hibiscus; Insulin Receptor Substrate Proteins; Insulin Resistance; Kidney; Linagliptin; Male; Phosphorylation; Polyphenols; Purines; Quinazolines; Rats, Sprague-Dawley; Vimentin | 2014 |
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hypoglycemic Agents; Linagliptin; Male; Mice, Inbred C57BL; Neointima; Purines; Quinazolines; Vascular System Injuries | 2014 |
EGFR inhibition protects cardiac damage and remodeling through attenuating oxidative stress in STZ-induced diabetic mouse model.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Cell Line; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Models, Animal; ErbB Receptors; Fibrosis; Male; Mice; Myocardium; Oxidative Stress; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Signal Transduction; Tyrphostins; Ventricular Remodeling | 2015 |
Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.
Topics: Animal Feed; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-Fat; Glial Fibrillary Acidic Protein; Hypoglycemic Agents; Insulin; Linagliptin; Male; Metformin; Microscopy, Fluorescence; Neuroglia; Neurons; Pain; Pain Management; Pain Measurement; Pioglitazone; PPAR gamma; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Thiazolidinediones | 2015 |
The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Angiopathies; ErbB Receptors; Hyperglycemia; Lapatinib; Male; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Phosphorylation; Primary Cell Culture; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction | 2015 |
Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.
Topics: Adenine; Animals; Cell Differentiation; Cells, Cultured; Class I Phosphatidylinositol 3-Kinases; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; T-Lymphocytes | 2016 |
Impact of PAMAM delivery systems on signal transduction pathways in vivo: Modulation of ERK1/2 and p38 MAP kinase signaling in the normal and diabetic kidney.
Topics: Animals; Blood Glucose; Cyclic N-Oxides; Dendrimers; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; ErbB Receptors; Kidney; Male; MAP Kinase Signaling System; Phosphorylation; Quinazolines; Rats; Spin Labels; Tyrphostins | 2016 |
Design and synthesis of quinazoline-3,4-(4H)-diamine endowed with thiazoline moiety as new class for DPP-4 and DPPH inhibitor.
Topics: Animals; Antioxidants; Biphenyl Compounds; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Free Radicals; Hypoglycemic Agents; Molecular Docking Simulation; Picrates; Quinazolines; Rats, Wistar; Thiazoles | 2017 |
Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats.
Topics: Aldehyde Reductase; Animals; Axons; Cell Death; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Enzyme Inhibitors; Ganglia, Spinal; Male; Nerve Degeneration; Polymers; Quinazolines; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Sural Nerve; Treatment Outcome; Wallerian Degeneration | 2009 |
Role of epidermal growth factor receptor (EGFR) in corneal remodelling in diabetes.
Topics: Animals; Collagen; Cornea; Corneal Stroma; Diabetes Mellitus, Experimental; Enzyme Inhibitors; ErbB Receptors; Female; Microscopy, Electron; Proteoglycans; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Tissue Distribution; Tyrphostins | 2009 |
EGFR-PLCgamma1 signaling mediates high glucose-induced PKCbeta1-Akt activation and collagen I upregulation in mesangial cells.
Topics: Animals; Blood Glucose; Cells, Cultured; Collagen Type I; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Estrenes; Female; Male; Mesangial Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phospholipase C gamma; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Proto-Oncogene Proteins c-akt; Pyrrolidinones; Quinazolines; Rats; Rats, Sprague-Dawley; RNA Interference; Tyrphostins; Up-Regulation | 2009 |
The involvement of aldose reductase in alterations to neurotrophin receptors and neuronal cytoskeletal protein mRNA levels in the dorsal root ganglion of streptozotocin-induced diabetic rats.
Topics: Aldehyde Reductase; Animals; Cytoskeletal Proteins; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inhibitors; Ganglia, Spinal; Male; Nerve Tissue Proteins; Neurofilament Proteins; Neurons; Polymers; Quinazolines; Rats; Receptors, Nerve Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tubulin | 2010 |
[Gefitinib improves insulin sensitivity in Wistar diabetes rats models].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gefitinib; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Phosphatidylinositol 3-Kinases; Quinazolines; Rats; Rats, Wistar | 2009 |
The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
Topics: Animals; Chemokine CXCL2; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Epithelial Cells; Female; Glucagon-Like Peptide 1; Inflammation; Keratinocytes; Linagliptin; Macrophage Inflammatory Proteins; Macrophages; Mice; Mice, Inbred C57BL; Mice, Obese; Myofibroblasts; Neutrophils; Purines; Quinazolines; Wound Healing | 2012 |
DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Linagliptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Oxidative Stress; Purines; Quinazolines; Streptozocin; Telmisartan; Treatment Outcome | 2012 |
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Linagliptin; Male; Mice; Obesity; Purines; Quinazolines; Stroke; Sulfonylurea Compounds | 2013 |
Synthesis and antihyperglycemic activity of suitably functionalized 3H-quinazolin-4-ones.
Topics: Animals; Area Under Curve; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Streptozocin; Structure-Activity Relationship | 2003 |
Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1).
Topics: Animals; Cyclosporine; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Enzyme Inhibitors; Graft Rejection; Immunosuppressive Agents; Islets of Langerhans Transplantation; Janus Kinase 3; Major Histocompatibility Complex; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protein-Tyrosine Kinases; Quinazolines | 2003 |
The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery.
Topics: Animals; Benzothiazoles; Body Weight; Carotid Arteries; Diabetes Mellitus, Experimental; Enzyme Inhibitors; ErbB Receptors; Female; Genes, erbB-1; Genes, erbB-2; Genistein; In Vitro Techniques; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Tyrphostins; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2005 |
Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed.
Topics: Angiotensin II; Animals; Carbachol; Cell Line; Diabetes Mellitus, Experimental; Endothelin-1; ErbB Receptors; Female; Genistein; Histamine; Humans; In Vitro Techniques; Mesenteric Arteries; Mesenteric Veins; Norepinephrine; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Streptozocin; Tyrphostins; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2005 |
The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Cholesterol, Dietary; Diabetes Mellitus, Experimental; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Malondialdehyde; Quinazolines; Quinazolinones; Rats | 2005 |
Effect of centpiperalone in insulin deficient diabetes.
Topics: Animals; Blood Glucose; Cricetinae; Diabetes Mellitus, Experimental; Female; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Piperazines; Quinazolines; Quinazolinones; Rats | 1980 |
Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Cataract; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Glucose Tolerance Test; Glutathione; Immunosuppressive Agents; Insulin; Lens, Crystalline; Male; Quinazolines; Rats; Sodium-Potassium-Exchanging ATPase; Sorbitol; Tacrolimus | 1997 |
Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats.
Topics: Animals; Blood Flow Velocity; Diabetes Mellitus, Experimental; Diacylglycerol Kinase; Diglycerides; Enzyme Inhibitors; Fluorescein Angiography; Hyperglycemia; Indoles; Isoenzymes; Male; Maleimides; Piperidines; Protein Kinase C; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Retina; Retinal Vessels | 1997 |
The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats.
Topics: Aldehyde Reductase; Animals; Blood Flow Velocity; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Enzyme Inhibitors; Male; Neural Conduction; Quinazolines; Rats; Rats, Sprague-Dawley; Reaction Time; Sciatic Nerve; Streptozocin | 2001 |
Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract.
Topics: Administration, Topical; Aldehyde Reductase; Animals; Cataract; Diabetes Mellitus, Experimental; Lens, Crystalline; Male; Quinazolines; Rats; Rats, Inbred Strains; Retina; Sorbitol; Streptozocin | 1991 |
[Quantitative study of rat diabetic cataract, by the relaxation times of nuclear magnetic resonance].
Topics: Aldehyde Reductase; Animals; Cataract; Diabetes Mellitus, Experimental; Magnetic Resonance Spectroscopy; Male; Quinazolines; Rats; Time Factors | 1991 |
A novel hypoglycemic compound.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dogs; Guinea Pigs; Haplorhini; Hypoglycemic Agents; Macaca; Pancreas; Pancreatectomy; Piperazines; Quinazolines; Rabbits; Rats; Species Specificity | 1973 |